Rheumatology · London
RA biologics infusion, by a consultant rheumatologist.
A dedicated day unit for private rheumatoid arthritis biologics - TNFα inhibitors, rituximab, tocilizumab, abatacept and JAK inhibitors under NICE TA375, with full pre-biologic screening and DAS28 response tracking.
Why patients choose us
- 01
A consultant rheumatologist, in a dedicated infusion unit
Not a shared oncology chair. A named rheumatologist with a high biologics case volume, in a day unit built for infusion monitoring.
- 02
The right biologic for your disease
TNFi is not always the answer. For seropositive erosive RA, IL-6 or B-cell depletion may fit better. We match to phenotype before we prescribe.
- 03
Independent, and free
We are paid by no clinic and no manufacturer, so the recommendation is impartial and costs you nothing.
Indicative pricing
What a private RA biologic costs in the UK.
Indicative ranges across our London partner units. Send the rheumatology letter and we quote firm figures across two or three options.
In short
A private RA biologic in our network: £8,000–£24,000/year drug plus £450–£850 per infusion.
| Service | Indicative range | Typical schedule | Turnaround |
|---|---|---|---|
| Initial rheumatology consultation and DAS28 | £280–£450 | 45–60 min | Same visit |
| Pre-biologic screening panel (TB, hep, HIV, CXR) | £420–£680 | 60 min | 5–7 days |
| Infusion administration (per session, all-in) | £450–£850 | 2–4 hours | Same visit |
| Infliximab (Remicade) annual drug cost | £8,000–£12,000 | 6–8 weekly | Ongoing |
| Rituximab (MabThera) 2 x 1g course | £3,600–£5,200 | 6 monthly | Ongoing |
| Tocilizumab or abatacept annual drug cost | £10,000–£16,000 | Monthly IV | Ongoing |
| JAK inhibitor (baricitinib, upadacitinib) annual | £9,000–£14,000 | Oral daily | Ongoing |
Prices vary by unit, by drug (originator versus biosimilar), and by dosing weight for weight-based biologics such as infliximab and tocilizumab. Insurance often covers biologics fully where clinically indicated - we confirm cover before booking.
The problem
The right biologic, the right screening, the right unit.
A biologic started without proper TB screening, or a JAK inhibitor started without ORAL Surveillance counselling, is a preventable harm. We stop that happening.
-
Is a biologic the right next step?
Or would optimising methotrexate, adding leflunomide, or a course of steroid actually get you there? We answer that first.
-
Which class fits your phenotype?
TNFi for early moderate disease, rituximab for seropositive erosive RA, IL-6 for systemic features, JAK oral for convenience - matched to you.
-
Where will you be infused?
A dedicated rheumatology day unit with resuscitation, hourly obs and infusion-nurse cover - not a shared oncology chair.
The journey
From referral to DAS28 response - what happens, in order.
One team from first message to 6-month response review - screening, first infusion, and every safety blood along the way.
Phase 1 · Before your infusion
Concierge, off-stage for you
Phase 2 · On the day
A few hours at the day unit
Phase 3 · After
DAS28 tracking, blood monitoring
- 01
Before
You send us the rheumatology letter
A short, confidential form. DAS28 or CDAI, current DMARDs, MTX dose and tolerance, seropositivity and any prior biologics.
- 02
Before
We come back with a recommendation
Within one working day: which biologic class fits, whether SC or IV suits your life, and an indicative annual cost.
- 03
Before
Pre-biologic screening
TB IGRA plus chest X-ray, hepatitis B and C, HIV, pregnancy test, and a vaccination review. Pneumococcal and annual influenza before start.
- 04
On the day
Arrival at the day unit
Baseline observations, IV access, and a chat with the infusion nurse. Hydrocortisone and paracetamol premedication for infliximab and rituximab.
- 05
On the day
The infusion itself
2 to 4 hours depending on drug. Hourly observations during your first infusion. Post-infusion observation for 30 to 60 minutes before discharge.
- 06
On the day
Home the same day
Written aftercare, a 24/7 contact number, and home a few hours after start. You can usually drive yourself unless premedication makes you drowsy.
- 07
After
DAS28 monitoring and dose review
DAS28 and patient global at 3 and 6 months. A primary non-responder at 12 to 16 weeks triggers a class switch under NICE TA375.
Typical end-to-end: 2–3 weeks to first infusion. Response review: 3 and 6 months. Ongoing monitoring: every 3 months.
When it helps
When a biologic is the right step - and when it is not.
The clinical situations that lead patients to a biologics clinic, plus the flags that mean we screen and counsel harder before we prescribe.
-
MTX-inadequate response after 6 months
Persistent DAS28 above 5.1, or above 3.2 with structural damage, despite methotrexate at 20 to 25mg weekly. The NICE TA375 entry point for a biologic.
-
MTX intolerance or contraindication
Hepatotoxicity, cytopenia, severe nausea, or a planned pregnancy. Options include leflunomide combination or moving straight to a biologic monotherapy.
-
Erosive seropositive RA
Anti-CCP or RF positive with radiographic erosions. Early biologic escalation reduces long-term joint damage - rituximab and IL-6 blockade fit well.
-
Extra-articular manifestations
Rheumatoid nodules, vasculitis, interstitial lung disease or scleritis. Rituximab is often preferred; TNFi may worsen certain lung phenotypes.
-
Primary or secondary TNFi failure
No response at 12 to 16 weeks (primary), or lost response after initial gain (secondary). Switch class - IL-6, CTLA-4 or JAK - rather than another TNFi.
-
Latent TB or hepatitis B carrier
A positive IGRA needs isoniazid prophylaxis before starting a TNFi. Hep B carriers need antiviral cover and hepatology input - not a reason to withhold treatment.
-
Cardiovascular risk and ORAL Surveillance
For patients over 65, smokers or with prior CV events, JAK inhibitors carry an increased MACE and VTE signal. A biologic is usually preferred first.
-
Red flag: active infection or malignancy
Active sepsis, untreated tuberculosis, or recent solid or haematological malignancy needs specialist review before any biologic is started.
Drug options
RA biologics are a family - and JAK inhibitors sit beside them.
What each option actually involves, and which fits which phenotype. NICE TA375, TA466, TA744 and TA676 shape the sequencing.
-
TNFα inhibitors (Humira, Enbrel, Cimzia, Simponi)
Subcutaneous injection weekly to monthly, self-administered at home. The default first-line biologic under NICE TA375 in MTX-inadequate RA.
-
Infliximab (Remicade) IV
A chimeric TNFα antibody given as an IV infusion at 0, 2 and 6 weeks then every 6 to 8 weeks. Hydrocortisone premedication reduces infusion reactions.
-
Rituximab (MabThera) IV
Anti-CD20 B-cell depletion. Two 1g IV infusions two weeks apart, repeated every 6 months. Particularly effective in seropositive RA and RA-ILD.
-
Tocilizumab (RoActemra)
IL-6 receptor blockade, monthly IV or weekly SC. Useful when TNFi has failed, in systemic features, or when co-existent giant-cell arteritis is a factor.
-
Abatacept (Orencia)
CTLA-4 Ig - blocks T-cell co-stimulation. Monthly IV or weekly SC. Favoured in older patients or those with a heavy infection burden.
-
JAK inhibitors (Olumiant, Xeljanz, Rinvoq, Jyseleca)
Oral once-daily small-molecule JAK inhibitors under TA375, TA466, TA744 and TA676. Convenient but require ORAL Surveillance-informed CV and malignancy screening.
-
Biosimilar switching
Adalimumab, infliximab, etanercept and rituximab biosimilars deliver equivalent outcomes at lower cost. We flag when a biosimilar switch is appropriate.
-
Second-opinion review
A specialist review of your rheumatology letters, DAS28 trend and prior biologics - sometimes the right answer is optimise MTX, not add a biologic.
Our London network
A small panel of consultant rheumatologists, we picked them.
Kellgren Centre Manchester, King's Private Rheumatology, HCA Wellington Rheumatology, Chelsea and Westminster Private, Guy's and St Thomas' Private, Imperial Private Charing Cross, plus a Bath (RNHRD) referral pathway.
Selection criteria
How we choose every rheumatologist in our network.
-
Consultant rheumatologists with high biologics case volumes, not general clinics
-
Dedicated infusion day units with resuscitation, nursing cover and hourly obs
-
Full pre-biologic screening pathways (TB IGRA, hep panel, HIV, CXR) in-house
-
Multidisciplinary input from respiratory, hepatology and ID when needed
Safety and monitoring
What to expect - honestly.
Biologics are well-established and effective. The things worth planning are your screening panel, infection vigilance, JAK-specific counselling, and DAS28 review windows.
-
Pre-biologic screening
TB IGRA plus chest X-ray, hepatitis B surface antigen and core antibody, hepatitis C, HIV, pregnancy test, and a full vaccination review before your first dose.
-
Vaccination boost
Pneumococcal (PCV13 then PPV23) and annual inactivated influenza before starting. Shingrix for eligible patients. Live vaccines (yellow fever, MMR, live shingles) are contraindicated.
-
Infusion reactions
Mild flushing or urticaria in 5 to 10% of first infusions with infliximab or rituximab. Premedication with hydrocortisone and paracetamol reduces incidence. Anaphylaxis is rare but planned for.
-
Infection risk
A modest increase in serious bacterial infection with all biologics. Any fever above 38C, productive cough, dysuria or cellulitis needs same-day contact and treatment interruption.
-
TB reactivation with TNFi
TNFα inhibitors carry a real reactivation risk. Latent TB (positive IGRA) needs isoniazid for at least 4 weeks before starting the biologic, continued to 6 months.
-
ORAL Surveillance and JAK inhibitors
The ORAL Surveillance trial showed an increased signal for MACE, VTE and malignancy with tofacitinib versus TNFi in RA over 50 with a CV risk factor. We screen and counsel before prescribing.
-
Pregnancy and biologics
Certolizumab (Cimzia) has minimal placental transfer and is the preferred TNFi in pregnancy. Rituximab and JAK inhibitors are avoided. All decisions are shared with obstetrics.
-
DAS28 response at 3 and 6 months
A EULAR good response (DAS28 fall of at least 1.2 to below 3.2) at 6 months justifies continuation. Non-response at 12 to 16 weeks triggers a class switch.
-
Red flags after infusion
Severe rash, breathing difficulty, chest pain, high fever, unusual bruising or bleeding, or signs of infection - call the unit or go to A&E the same day.
Reading your rheumatology letter
Your biologics letter in four parts. Read the last one first.
Whichever biologic was chosen, the letter your rheumatologist sends you keeps to the same shape.
A quiet reminder
Rheumatology language is precise and can read coldly - we translate it for you.
If you would like us to talk you through the letter before your review, just ask.
- 01 Header
Diagnosis, seropositivity and DAS28 baseline
RF and anti-CCP status, disease duration, erosions on imaging, and baseline DAS28 with tender and swollen joint counts and CRP.
- 02 Regimen
Drug, dose and infusion schedule
The chosen biologic, dose in mg or mg/kg, infusion interval, premedication protocol, and self-administration training if SC.
- 03 Findings
Screening results and reactions
IGRA, hepatitis panel, HIV, CXR interpretation, vaccination status, plus any infusion reactions and their management.
- 04 Impression
Response plan and review interval
Read this first: when DAS28 will be repeated, when a switch decision is made, and the safety-monitoring blood schedule.
Recognised by major UK insurers
Cover for RA biologics varies by insurer - usually funded where NICE TA375 criteria are met. We confirm cover before booking.
Frequently asked
Everything we get asked about RA biologics.
Quick answers on NICE TA375, TB screening, JAK safety, pregnancy and how we choose the right drug.
-
When am I eligible for a biologic under NICE TA375?
NICE TA375 recommends a biologic (bDMARD) for adults with active RA whose disease has not responded to at least two conventional DMARDs including methotrexate. Active is defined as DAS28 above 5.1, or above 3.2 with radiographic damage. A biologic is combined with methotrexate where possible, and continued only if DAS28 falls by at least 1.2 at 6 months.
-
What is the difference between a TNFi, IL-6 blocker, B-cell depleter and JAK inhibitor?
TNFα inhibitors (adalimumab, etanercept, infliximab, certolizumab, golimumab) block the TNF cytokine and are first-line. IL-6 blockade (tocilizumab) targets a different cytokine and is useful in TNFi failure. Rituximab depletes CD20+ B cells and suits seropositive RA. JAK inhibitors (baricitinib, tofacitinib, upadacitinib, filgotinib) are oral small molecules that block intracellular signalling.
-
How much does a biologic cost me privately in the UK?
Drug costs run £8,000 to £24,000 per year depending on the molecule and whether a biosimilar is used. Infusion administration is £450 to £850 per session all-in. An initial rheumatology consultation and pre-biologic screening panel is £700 to £1,100. We confirm firm figures for your regimen within one working day.
-
Why do I need TB screening before a biologic?
TNFα inhibitors, in particular, reactivate latent tuberculosis. Every patient has an interferon-gamma release assay (IGRA) blood test plus a chest X-ray before their first dose. A positive IGRA means at least 4 weeks of isoniazid prophylaxis (continued for 6 months) before the biologic starts. Hepatitis B and C, HIV and a pregnancy test are done alongside.
-
What is the ORAL Surveillance concern with JAK inhibitors?
ORAL Surveillance was a post-authorisation safety trial that compared tofacitinib with TNFi in RA patients over 50 with at least one cardiovascular risk factor. It showed a higher rate of major adverse cardiovascular events, venous thromboembolism and malignancy with tofacitinib. The signal is now considered a class effect for JAK inhibitors, which means we screen carefully and usually prefer a biologic first in this group.
-
Can I have a biologic if I want to become pregnant?
Yes, with the right choice. Certolizumab pegol (Cimzia) has minimal placental transfer and is the preferred TNFi in pregnancy and breastfeeding. Etanercept and adalimumab are also considered safe in the first two trimesters. Rituximab, tocilizumab and JAK inhibitors are avoided in pregnancy. Every decision is shared with your obstetrician.
Ready to start
Send us your rheumatology letter. We come back within a working day.
An indicative regimen, an indicative annual cost, and a screening plan. If a biologic is not the right next step, we say so.
Related
Looking for something else?
-
Asthma biologics clinic
Omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab.
Learn more -
Dupilumab for eczema
Atopic dermatitis IL-4/13 blockade in a private clinic.
Learn more -
Omalizumab for urticaria
Anti-IgE for chronic spontaneous urticaria.
Learn more -
Osteoporosis clinic
Bisphosphonates, denosumab, romosozumab, teriparatide.
Learn more -
Rheumatoid arthritis
The condition guide - symptoms, diagnosis and treatment.
Learn more -
Psoriatic arthritis
PsA condition guide - biologics, JAK and enthesitis.
Learn more